ASH 2025 | Understanding the evolving treatment landscape of Ph+ ALL in the US
Marlise Luskin, MD, MSCE, Dana-Farber Cancer Institute, Boston, MA, briefly discusses a retrospective cohort study examining real-world treatment patterns, outcomes, and unmet needs in patients with Ph-positive acute lymphoblastic leukemia (Ph+ ALL) receiving tyrosine kinase inhibitors (TKIs) in the United States, highlighting that this analysis aimed to understand the evolving treatment landscape in this disease. This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
This is a study that I’ve done in collaboration with colleagues to really just understand the treatment landscape of Ph-positive ALL. That field is moving very quickly with new treatments for patients in terms of novel tyrosine kinase inhibitors, third-generation tyrosine kinase inhibitors like ponatinib, and ongoing studies evaluating asciminib in both the frontline and relapsed setting...
This is a study that I’ve done in collaboration with colleagues to really just understand the treatment landscape of Ph-positive ALL. That field is moving very quickly with new treatments for patients in terms of novel tyrosine kinase inhibitors, third-generation tyrosine kinase inhibitors like ponatinib, and ongoing studies evaluating asciminib in both the frontline and relapsed setting. So we have novel new TKIs as well as developments in what those TKIs are combined with, including blinatumomab and evolving use of novel therapies like blinatumomab and transplantation. So this study was really to look at the treatment landscape and how it’s been evolving over the past few years, which will really set the stage for us to monitor the changes going forward. We’re excited that the treatment landscape has changed, but it’s really important to understand how patients are being treated and understand their outcomes so we can monitor our progress moving forward. So excited to present that abstract.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
